6%), (G2) cerebellum in 2/30(6 6%), (G3) supratentorial associate

6%), (G2) cerebellum in 2/30(6.6%), (G3) supratentorial associated with seizures in 16/30 this website (53.3%), and (G4) supratentorial without seizures in 7/30 (23.3%). Surgical resection was performed in 26 out of 30 (86.6%) patients. The mean follow-up period was 4.1 years. Of 15 children followed-up with preoperative seizures, all were rendered seizure-free after surgery. Conclusions: For symptomatic solitary cavernous malformation, the treatment of choice is complete microsurgical

excision preceded by careful anatomical and functional evaluation. For multiple cavernous malformation or asymptomatic patients, the treatment modalities must be cautiously considered.”
“Purpose: The cytotoxic effects of hexane extracts of Cassia alata and Psidium guajava leaves were evaluated in OV2008 ovarian and Kasumi-1 leukemia cancer cell lines, respectively.

Methods: The cancer cells were exposed to various concentrations of either C. alata (100 – 180 mu g/ml) or P. guajava (100 – 500 mu g/ml) leaf extract for 24 h.

Following treatment, the cells were evaluated using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to determine the cytotoxic effect of the extracts. C. alata extract was also analyzed using high performance liquid chromatography (HPLC).

Results: C. alata and P. guajava extracts produced significant (p < 0.05) cytotoxicity in OV2008 and Kasumi-1 cell lines, respectively. The IC50 values were 160 mu g/ml for C. alata Z-DEVD-FMK and 200 mu g/ml for P guajava. Further, the cytotoxicity exhibited by C. alata might be attributable to the flavonoid, kaempferol, which was identified as a constituent of the extract.

Conclusion: The results suggest that further chemical analysis and mechanistic investigations should be conducted on P. guajava and C. alata extracts to validate their potential uses for anticancer therapy.”
“Background and objective: Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder of the upper lobe, whereas emphysema is usually associated with lower lobe fibrosis. Although CPFE might increase the risk of lung cancer, the prevalence of CPFE in patients with lung cancer

and the incidence of lung cancer in patients with CPFE are unknown. The objective of this study was to determine the prevalence of CPFE in lung cancer patients and to assess the clinical features of these patients.

Methods: A total click here of 1143 patients with lung cancer were reviewed. Based on HRCT performed at diagnosis of lung cancer, patients were categorized into four groups: normal, emphysema, fibrosis and CPFE. The clinical characteristics of patients with CPFE were compared with those of the other groups.

Results: CPFE, emphysema and fibrosis were identified in 101 (8.9%), 404 (35.3%) and 15 (1.3%) patients with lung cancer, respectively. The median overall survival of CPFE patients (n = 101, 10.8 months) was significantly less than that of normal patients (n = 623, 53.0 months) or that of patients with emphysema alone (n = 404, 21.

Comments are closed.